lorcaserin (Belviq)

From Aaushi
Jump to navigation Jump to search
[1][2][3][4][5][6][7][8][9][10][11]

Introduction

FDA did not approve 2010[2]

FDA-approval recommended May 2012[4]; FDA-approved June 2012[5]

FDA asked Eisai to voluntary withdraw lorcaserin from the U.S. markket Feb 13, 2020 due to increased risk for cancer[11]

Indications

Dosage

10 mg PO BID

Adverse effects

Mechanism of action

More general terms

References

  1. ↑ Smith SR et al Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management New Engl J Med 2010, 363:245-256 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/20647200 <Internet> http://content.nejm.org/cgi/content/short/363/3/245
  2. ↑ 2.0 2.1 2.2 FDA Issues Complete Response Letter for Lorcaserin New Drug Application Arena Pharmaceuticals, October 23, 2010 http://invest.arenapharm.com/releasedetail.cfm?ReleaseID=521977
  3. ↑ No F.D.A. Approval for New Diet Pill New York Times October 23, 2010 http://topics.nytimes.com/top/reference/timestopics/people/p/andrew_pollack/index.html?inline=nyt-per
  4. ↑ 4.0 4.1 Anonymous FDA advisers recommend approval of lorcaserin; could be first new weight loss drug in a decade Associated Press, May 10, 2012 http://www.washingtonpost.com/politics/fda-advisers-recommend-approval-of-lorcaserin-could-be-first-new-weight-loss-drug-in-a-decade/2012/05/10/gIQA1jVMGU_story.html
    FDA Briefing Document Lorcaserin Hydrochloride Tablets, 10 mg Sponsor: Arena Pharmaceuticals Endocrinologic and Metabolic Drugs Advisory Committee Meeting, May 10, 2012 http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM303198.pdf
  5. ↑ 5.0 5.1 FDA News Release: June 27, 2012 FDA approves Belviq to treat some overweight or obese adults http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm309993.htm
  6. ↑ Shyh G, Cheng-Lai A. New antiobesity agents: lorcaserin (Belviq) and phentermine/ topiramate ER (Qsymia). Cardiol Rev. 2014 Jan-Feb;22(1):43-50. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/24304809
  7. ↑ 7.0 7.1 Khera R, Murad MH, Chandar AK et al. Association of pharmacological treatments for obesity with weight loss and adverse events: A systematic review and meta-analysis. JAMA 2016 Jun 14; 315:2424 PMID: https://www.ncbi.nlm.nih.gov/pubmed/27299618
  8. ↑ 8.0 8.1 8.2 Bohula EA, Wiviott SD, McGuire DK et al. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med 2018 Aug 26; PMID: https://www.ncbi.nlm.nih.gov/pubmed/30145941 Free Article https://www.nejm.org/doi/10.1056/NEJMoa1808721
    Ingelfinger JR, Rosen CJ. Lorcaserin - Elixir or liability? N Engl J Med 2018 Aug 26 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30145932 Free Article https://www.nejm.org/doi/10.1056/NEJMe1810855
  9. ↑ 9.0 9.1 Bohula EA et al. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): A randomised, placebo-controlled trial. Lancet 2018 Oct 4; PMID: https://www.ncbi.nlm.nih.gov/pubmed/30293771 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32328-6/fulltext
    Unamuno X, Fruhbeck G. Lorcaserin: Balancing efficacy with potential risks. Lancet 2018 Oct 4 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30293772 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32460-7/fulltext
  10. ↑ 10.0 10.1 FDA Safety Watch. Feb 14, 2020 Belviq, Belviq XR (lorcaserin): Drug Safety Communication - Due to Possible Increased Risk of Cancer. https://www.fda.gov/safety/medical-product-safety-information/belviq-belviq-xr-lorcaserin-drug-safety-communication-due-possible-increased-risk-cancer
  11. ↑ 11.0 11.1 11.2 Otto A Lorcaserin (Belviq) Withdrawn From US Market Due to Cancer Risk. Medscape - Feb 13, 2020. https://www.medscape.com/viewarticle/925253
Retrieved from "https://aaushi.info/w/index.php?title=A338983&oldid=1042651"